Amgen Sensipar Label Prepares For Off-Label Use In Pre-Dialysis Market
This article was originally published in The Pink Sheet Daily
Review documents show that FDA crafted the calcimimetic's label with the expectation of off-label use in secondary hyperparathyroidism patients not yet on dialysis. Concern about Sensipar's potential to cause QT prolongation via hypocalcemia was a key factor in FDA's rejection of Amgen's request for approval in the pre-dialysis population.
You may also be interested in...
Amgen's chronic kidney disease treatment Sensipar includes precautions on hypocalcemia
The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.
Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.